Navigation Links
BUSM awarded $9 million to investigate treatment for sickle cell disease using iPS cells
Date:7/25/2011

(Boston) - Researchers from the Boston University School of Medicine (BUSM) were recently awarded a five-year $9 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to mass-produce sickle cell anemia-specific induced Pluripotent Stem (iPS) cells. Under the direction of principal investigators Martin H. Steinberg, MD and George Murphy, PhD, the researchers propose making iPS cells from the blood of patients with sickle cell disease to better understand how certain genes are involved in the disease.

This initiative, which is being done in collaboration with Boston Medical Center (BMC), brings together two of the most dynamic entities at the Boston University Medical Campus: the Center of Excellence in Sickle Cell Disease, directed by Steinberg, and the Center for Regenerative Medicine (CReM), which is co-directed by Murphy, Gustavo Mostoslavsky, MD, PhD, and Darrell Kotton, MD.

iPS cells are derived by reprogramming adult cells into a primitive stem cell state. This process results in the creation of cells that are similar to embryonic stem (ES) cells in terms of their capability to differentiate into different types of cells. It is now widely accepted that iPS cells share many of the characteristics ES cells, including gene expression profiles, epigenetic signatures and pluripotency. iPS cells can be generated from mature somatic cells, such as skin or blood cells, allowing for the development of patient-specific cells and tissues that should not elicit inappropriate immune responses, making them a powerful tool for biological research and a resource for regenerative medicine.

Sickle cell anemia, an orphan disease of African Americans, is noted for its extensive morbidity and high mortality. Only one Food and Drug Administration (FDA) approved drug is available for its pathophysiologically based treatment. This agent, hydroxyurea, works through its ability to induce fetal hemoglobin (HbF) expression, which thwarts sickle hemoglobin polymerization. Not all patients respond to this treatment, so additional HbF inducing drugs are needed.

"This funding will allow us to create the largest library of sickle cell disease-specific iPS cell lines in the world," said Murphy, assistant professor of Medicine and Hematology-Oncology at BUSM. "It enables the creation of an in vitro system for the study of sickle cell anemia in the exact genetic context of the patients."

Using a novel excisable reprogramming vector, they will generate 'clinical grade' human iPS cells free of any residual reprogramming transgenes. These directly differentiated sickle iPS cells will be used to produce an unlimited supply of erythroid-lineage cells to better understand HbF genetic regulation and perform pre-clinical small molecule drug screens.

"These studies will illuminate how specific genes behave in different tissues and should clarify the mechanisms by which a gene associated with a disease affects the biology of different tissues," said Susan B. Shurin, MD, acting director of the National Institutes of Health's (NIH) NHLBI, which is funding most of the studies. "Understanding the cellular and tissue biology will allow us to develop and test new therapies and prevention methods. These approaches using iPS cells on a large scale could improve the predictive value of preclinical testing, benefit regenerative medicine and reduce the need for animal models of disease."

"We have an opportunity here to study tissue-specific cells on a large scale, including how gene variants are expressed and alter a tissue's behavior," said Cashell Jaquish, PhD, a program officer in the NHLBI's Division of Cardiovascular Sciences. "That is something we haven't been able to get near before" because the technology was not available. The opportunities are great because genome-wide association studies have identified multiple potentially important genetic variants, she added.

"Ultimately, we hope to translate these findings into clinically efficacious treatments," said Steinberg, also a professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at BUSM.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Grants awarded to help bring promising bioscience discoveries to market
2. Johns Hopkins researchers awarded $32 million
3. UTMB-led researchers awarded $7.8 million for Gulf spill study
4. Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack
5. Patent for arrays of nanoscale electrical probes awarded to NJIT today
6. UTHealth awarded FEMA grant to explore novel obesity risk factor among firefighters
7. Caltech scientist awarded $5 million grant for plant research
8. Karcsi Global, LLC Awarded NEC Latin America Contract
9. Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize
10. Research Institute of the MUHC awarded $1.4M grant
11. Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
Breaking Biology News(10 mins):
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients found in ... malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols ...
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
(Date:5/19/2016)... MAPLE RIDGE, British Columbia , May 19, ... of AdvanTec Global Innovations Inc. (AGI), based out ... recently added Greenlane Biogas Ltd. to its ... a 2-year contract manufacturing agreement. AFS along with ... Bending Technologies (ABT) is a vertically integrated industrial ...
(Date:5/19/2016)... SAN DIEGO , May 19, 2016 /PRNewswire/ ... (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced ... at creating the first cord blood based cancer ... a provisional patent application, Regen described a generation ... activity was potentiated by gene silencing.  The product ...
Breaking Biology Technology: